Literature DB >> 6146035

HTLV-I-specific antibody in AIDS patients and others at risk.

M Robert-Guroff, D W Blayney, B Safai, M Lange, E P Gelmann, J W Gutterman, P W Mansell, J L Goedert, J E Groopman, N H Steigbigel.   

Abstract

Serum samples from 440 acquired immunodeficiency syndrome (AIDS) patients or individuals at risk for AIDS were examined by the enzyme-linked immunosorbent assay technique for antibodies to HTLV-I core proteins. Specific antibodies were detected in 7% of AIDS patients, 7% of patients with lymphadenopathy, 0% of healthy homosexual men, and 12% of healthy Haitians. When findings in homosexual men were analysed separately, the prevalence for homosexual men with lymphadenopathy was 7% and for homosexuals with AIDS, 6%. Antibody titres ranged from 77 to 74 000. The antibody-positive cases included intravenous drug users, a Haitian AIDS patient, a recipient of multiple blood transfusions, and homosexual men. Haemophiliacs were not examined. Although HTLV-I-specific antibodies are more prevalent in AIDS patients than in healthy US donors, the difference is not sufficient to suggest an association of HTLV-I with the disease. The low rate may indicate an opportunisitic infection of AIDS patients by HTLV-I, or a crossreaction with the recently described HTLV variant, HTLV-III, believed to be the aetiological agent of AIDS. Whether HTLV-I normally exerts immune suppressive effects in vivo with biological consequences remains to be determined.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6146035     DOI: 10.1016/s0140-6736(84)91047-x

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  5 in total

1.  Differential response to the cytopathic effects of human T-cell lymphotropic virus type III (HTLV-III) superinfection in T4+ (helper) and T8+ (suppressor) T-cell clones transformed by HTLV-I.

Authors:  A De Rossi; G Franchini; A Aldovini; A Del Mistro; L Chieco-Bianchi; R C Gallo; F Wong-Staal
Journal:  Proc Natl Acad Sci U S A       Date:  1986-06       Impact factor: 11.205

2.  Concomitant infection of HTLV-I and HIV-1: prevalence of IgG and IgM antibodies in Washington, D.C. area.

Authors:  K S Chang; L C Wang; C L Gao; S Alexander; R C Ting; A Bodner; T Log; A F Kuo; P Strickland
Journal:  Eur J Epidemiol       Date:  1988-12       Impact factor: 8.082

Review 3.  Retroviral coinfections: HIV and HTLV: taking stock of more than a quarter century of research.

Authors:  Mark A Beilke
Journal:  AIDS Res Hum Retroviruses       Date:  2012-02       Impact factor: 2.205

Review 4.  HTLV-1, the Other Pathogenic Yet Neglected Human Retrovirus: From Transmission to Therapeutic Treatment.

Authors:  Nicolas Futsch; Renaud Mahieux; Hélène Dutartre
Journal:  Viruses       Date:  2017-12-21       Impact factor: 5.048

5.  Provirus Mutations of Human T-Lymphotropic Virus 1 and 2 (HTLV-1 and HTLV-2) in HIV-1-Coinfected Individuals.

Authors:  Karoline Rodrigues Campos; Adele Caterino-de-Araujo
Journal:  mSphere       Date:  2020-09-30       Impact factor: 4.389

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.